Market closedNon-fractional
Monte Rosa Therapeutics/GLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Ticker
GLUE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
130
Website
www.monterosatx.com
GLUE Metrics
BasicAdvanced
$286M
Market cap
-
P/E ratio
-$2.50
EPS
1.54
Beta
-
Dividend rate
Price and volume
Market cap
$286M
Beta
1.54
Financial strength
Current ratio
4.82
Quick ratio
4.686
Long term debt to equity
27.431
Total debt to equity
29.624
Management effectiveness
Return on assets (TTM)
-31.26%
Return on equity (TTM)
-68.28%
Valuation
Price to revenue (TTM)
237.454
Price to book
1.54
Price to tangible book (TTM)
1.54
Price to free cash flow (TTM)
-3.619
Growth
Earnings per share change (TTM)
2.75%
3-year earnings per share growth (CAGR)
-55.07%
What the Analysts think about GLUE
Analyst Ratings
Majority rating from 8 analysts.
GLUE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1M
∞%
Net income
-$32M
-3.92%
Profit margin
-3,190.00%
-∞%
GLUE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.71
-$0.70
-$0.58
-$0.53
-
Expected
-$0.70
-$0.72
-$0.33
-$0.57
-$0.54
Surprise
1.43%
-3.28%
73.28%
-7.48%
-
GLUE News
AllArticlesVideos
Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day
GlobeNewsWire·3 weeks ago
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
GlobeNewsWire·4 weeks ago
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Monte Rosa Therapeutics stock?
Monte Rosa Therapeutics (GLUE) has a market cap of $286M as of July 27, 2024.
What is the P/E ratio for Monte Rosa Therapeutics stock?
The price to earnings (P/E) ratio for Monte Rosa Therapeutics (GLUE) stock is 0 as of July 27, 2024.
Does Monte Rosa Therapeutics stock pay dividends?
No, Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Monte Rosa Therapeutics dividend payment date?
Monte Rosa Therapeutics (GLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Monte Rosa Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.